Search
Enzastaurin
go.drugbank.com/drugs/DB06486InvestigationalEnzastaurin, an investigational, targeted, oral agent, will be evaluated at more than 100 sites worldwide for the treatment of relapsed glioblastoma multiforme (GBM), an aggressive and malignant form of
Tedizolid phosphate
go.drugbank.com/drugs/DB09042ApprovedThis product is currently available as both an oral tablet and as a powder for intravenous injection.[L11232] … [L11232, A199086, A199050] Tedizolid was approved by the FDA on June 20, 2014, for sale by Cubist Pharmaceuticals as tedizolid phosphate (SIVEXTRO®).
Larazotide
go.drugbank.com/drugs/DB05645InvestigationalAn octapeptide inhibitor of paracellular permeability whose structure is derived from a protein (zonula occludens toxin) secreted by Vibrio cholerae for treatment of Coeliac disease.
Paliroden
go.drugbank.com/drugs/DB05454InvestigationalIt is indicated for use in Alzheimer's Disease and Parkinson’s. … Paliroden is an orally active neurotrophic, non-peptidic compound that activates synthesis of endogenous neurotrophines.
Salmon calcitonin
go.drugbank.com/drugs/DB00017ApprovedInvestigationalSynthetic peptide, 32 residues long formulated as a nasal spray.
AX200
go.drugbank.com/drugs/DB05093InvestigationalThe expression of the endogenous AX200 protein in the brain is increased after brain damage. … Thus, if this drug administered in the acute phase of stroke, the brain’s own protective action is supported.
Zatebradine
go.drugbank.com/drugs/DB21228ExperimentalThe usage of the INN stem '-bradine' in the name indicates that Zatebradine is a bradycardic agent. Zatebradine has a monoisotopic molecular weight of 456.26 Da.
Categories: Compounds used in a research, industrial, or household settingPirtobrutinib
go.drugbank.com/drugs/DB17472ApprovedInvestigationalA256758] Unlike BTK covalent inhibitors, such as [ibrutinib], that bind to the cysteine 481 (Cys481) amino acid within the active site of BTK, the inhibitory activity of pirtobrutinib is maintained even in … [L44863,L44873] In December 2025, pirtobrutinib received traditional FDA approval for adults with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) previously
VLTS-589
go.drugbank.com/drugs/DB05430InvestigationalVLTS-589 consists of plasmid encoding the angiomatrix protein Del-1 in conjunction with poloxamer 188 for the treatment of peripheral vascular disease.
Mefenamic acid
go.drugbank.com/drugs/DB00784ApprovedIt is an inhibitor of cyclooxygenase.
Synonyms: N-2,3-xylylanthranilic acid, N-(2,3-xylyl)-2-aminobenzoic acid